66th ASH Annual Meeting: 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I

Symposia: Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment Oral and Poster Abstracts
Poster

Research, Acute Myeloid Malignancies, Combination therapy, AML, Fundamental Science, Clinical Practice (Health Services and Quality), Translational Research, Assays, Clinical Research, Pediatric, Diseases, Treatment Considerations, Real-world evidence, Computational biology, Biological Processes, Myeloid Malignancies, Emerging technologies, Survivorship, Technology and Procedures, Molecular biology, Study Population, Human, Measurable Residual Disease , Molecular testing, Omics technologies

Halls G-H (San Diego Convention Center)

1568

Single-Cell Multi-Omic Analysis of AML MRD Reveals Differences in Clonal Architecture between Relapse and Non-Relapse Cases

Adam Sciambi, PhD¹^*, Daniel Mendoza, PhD¹^*, Kathryn Thompson¹^*, Lan W. Beppu²^*, Benjamin Geller, MSc³^*, Indira Krishnan, PhD¹^*, Lubna Nousheen, M.S.⁴^*, Shu Wang, PhD¹^*, Charlie Murphy, PhD⁴^*, Jerald P. Radich, MD⁵ and Todd E. Druley, MD, PhD⁶

¹Mission Bio, South San Francisco, CA
²Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
³R&D, Mission Bio, South San Francisco, CA
⁴Mission Bio, SOUTH SAN FRANCISCO, CA
⁵Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA
⁶Mission Bio, Inc, South San Francisco, CA

1569

Measurable Residual Disease Detection on Day 30 Post Haematopoietic Stem Cell Transplantation Predicts Clinical Outcome in Acute Myeloid Leukemia

Sze Pui Tsui, MSc^1,2^*, Ho-Wan Ip¹^*, Stephen Lam, PhD, MBBS,²^*, Chi Yeung Fung²^*, Wing-Hei Lai²^*, Edmond Shiu-Kwan Ma, MD³, Jocelyn P.Y. Sim²^* and Anskar Y.H. Leung, MD, PhD^2,4

¹Department of Pathology, Queen Mary Hospital, Hong Kong, China
²Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
³Department of Pathology, Hong Kong Sanitorium & Hospital, Hong Kong, China
⁴Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China

1570

Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Swe Mar Linn, MD¹, Nihar Desai, MBBS, MD, DM¹^*, Steven M. Chan, MD, PhD^1,2, Andre C. Schuh, MD, FRCPC^1,2, Aniket Banker, MD^1,2^*, Marta Beata Davidson, MD, PhD¹, Guillaume Richard-Carpentier, MD, FRCPC¹, Aron Shimmer, MD, PhD, FRCPC¹^*, Dawn C. Maze, MD, FRCPC, MSc^1,2, Karen Yee, MD, FRCPC¹^*, Mark D. Minden, MD, PhD¹^*, Vikas Gupta, MD, FRCP, FRCPath^1,2, Tracy Stockley, PhD²^*, Hassan Sibai, MD¹, Jose-Mario Capo-Chichi, PhD^2,3,4^*, Anne Maria Tierens, MD, PhD^2,3,4 and Dennis Dong Hwan Kim, MD, PhD^1,2,3

¹Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
²University of Toronto, Toronto, Canada
³Measurable residual disease working group, Princess Margaret Cancer Centre, Toronto, ON, Canada
⁴Laboratory Medicine Program, Toronto General Hospital, University Health Network, Toronto, Canada

1571

MRD Detection in Standard-Risk Pediatric AML Using Single-Cell RNA Sequencing

Rula Gladden, MD¹, Everett Fan²^*, Shruti Bhise³^*, Rhonda E. Ries, MA⁴^*, Rachel Ferina³^*, Sami B. Kanaan⁵^*, Mark A Mendoza⁶^*, Jobelle Peralta³^*, Rachel Gate, PhD⁷^*, Soheil Meshinchi, MD, PhD⁴ and Scott N Furlan, MD^4,8^*

¹Fred Hutch Cancer Center, Seattle, WA
²Fred Hutch Cancer Center, Seattle
³Fred Hutchinson Cancer Center, Seattle, WA
⁴Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
⁵Fred Hutchinson Cancer Research Center, Seattle, WA
⁶FRED HUTCHINSON CANCER RESEARCH CENTER, Seattle
⁷10X Genomics, Pleasanton, CA
⁸Department of Pediatrics, University of Washington, Mill Creek, WA

1572

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Wei-Ying Jen, MD, FRCPath, MA¹^*, Koji Sasaki, MD¹, Farhad Ravandi, MBBS², Tapan M. Kadia, MD¹, Sa A. Wang, MD³, Wei Wang, MD, PhD⁴^*, Sanam Loghavi, MD³, Naval Daver, MD⁵, Courtney D. DiNardo, MD, MSc⁶, Ghayas C. Issa, MD¹, Hussein A. Abbas, MD, PhD¹, Cedric Nasnas, MD¹^*, Alex Bataller, MD, PhD¹^*, Samuel Urrutia, MD⁷, Sherry Pierce, BSN, BA¹^*, Hagop M. Kantarjian, MD¹ and Nicholas J. Short, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
³Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX
⁵MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁷Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

1573

Epigenetic Adaptation Promotes Cellular Resilience in Senescence-like AML Cells

Manna Ahmed, MD^1,2^*, Dharmendra Kashyap, PhD^1,2^*, Christopher Miranda^1,2^*, Hannah Kim³^*, Martin P Carroll, MD⁴, Peter Abdelmessieh, MD¹^* and Cihangir Duy, PhD^1,2

¹Fox Chase Cancer Center, Philadelphia, PA
²Cancer Epigenetics Institute, Philadelphia, PA
³Temple University, Philadelphia
⁴Division of Hematology/Oncology, Department of Medicine, The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA

1574

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Paola Minetto, MD¹, Fabio Guolo, MD, PhD^1,2, Sara Rosellini³^*, Alfonso Piciocchi⁴^*, Giovanni Marconi, MD⁵, Ernesta Audisio, MD⁶^*, Giorgio Priolo⁷^*, Cristina Papayannidis, MD, PhD⁸, Maurizio Martelli, MD⁹^*, Giovanni Marsili⁴^*, Monica Bocchia, MD¹⁰^*, Francesco Lanza, MD¹¹^*, Albana Lico¹²^*, Fabio Ciceri, MD¹³^*, Matteo Giovanni Della Porta, MD¹⁴^*, Marco Frigeni¹⁵^*, Luisa Giaccone, MD, PhD¹⁶^*, Germana Beltrami, MD¹⁷^*, Erika Borlenghi, MD¹⁸^*, Maria Chiara Di Chio¹⁹^*, Carmine Selleri, MD²⁰, Enrico Crea, PharmD⁴^*, Irene Urbino²¹^*, Chiara Sartor, MD²²^*, Clara Minotti²³^*, Valentina Arena⁴^*, Jacopo Nanni, MD²²^*, Giorgia Simonetti, Ph.D.²⁴^*, Maria Teresa Bochicchio²⁵^*, Giuseppe Saglio, MD²⁶, Adriano Venditti²⁷, Marco Vignetti, MD⁴^*, Paola Fazi²⁸^*, Elisabetta Tedone¹^*, Giovanni Martinelli, M.D.²⁹ and Roberto Massimo Lemoli, MD^30,31^*

¹IRCCS Ospedale Policlinico San Martino, Genoa, Italy
²Hematology Unit, Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
³Servizio di Citofluorimetria, Dipartimento di Anatomia Patologica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
⁴GIMEMA Foundation, Rome, Italy
⁵Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Meldola, Italy
⁶SC EMATOLOGIA 2, AOU CITTA DELLA SALUTE E DELLA SCIENZA, OSPEDALE S. GIOVANNI BATTISTA MOLINETTE, Torino, ITA
⁷Haematology 2 - A.O.U San Giovanni Battista, Turin, ITA
⁸IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
⁹Hematology Section, Department of Traslational and Precision Medicine, Sapienza University of Rome, Roma, Italy
¹⁰Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
¹¹Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy
¹²Hematology Unit, Hematology Unit, San Bortolo Hospital, Vicenza, Italy, Vicenza, Italy
¹³Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. San Raffaele Scientific Institute, Milan, Italy
¹⁴IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
¹⁵Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
¹⁶Univesity of Torino, AOU Città Della Salute E Della Scienza Di Torino,, Torino, ITA
¹⁷U.O. Ematologia e terapie cellulari, IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy
¹⁸Hematology, ASST Spedali Civili, Brescia, Italy
¹⁹Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
²⁰Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy
²¹Department of Oncology and Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
²²Department of Medical and Surgical Sciences - University of Bologna, Bologna, Italy
²³Department of Translational and Precision Medicine, Division of Hematology, Sapienza University, Rome, Italy
²⁴IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy
²⁵IRCSS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l, Meldola, Italy
²⁶Dept. of Clinical and Biological Sciences, University of Turin, Turin, Italy
²⁷Department of Onco-Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy
²⁸GIMEMA Foundation, Data Center and Health Outcomes Research Unit, Rome, Italy
²⁹IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy
³⁰Clinic of Hematology, Department of Internal medicine (DiMI), University of Genoa, Genoa, Italy
³¹Clinica Ematologica, Dipartimento di Oncologia e Ematologia, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

1575

MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Ping Wu, M.D., Ph.D.¹^*, Wei Ling, M.D.¹^*, Chengwei Luo Luo, M.D.¹^*, Lisi Huang, M.D.¹^*, Ruohao Xu, Ph.D.¹^*, Xiaoling Liang¹^*, Jiaqi Tan, M.D.¹^*, Jinghua Wang, M.D.¹^*, Peilong Lai, M.D., Ph.D.¹^*, Suijing Wu, M.D.¹^*, Birong Li¹^*, Haijie Huang¹^*, Suxia Geng, M.D., Ph.D.¹^*, Xin Du, PhD² and Jianyu Weng, M.D., Ph.D.¹^*

¹Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
²Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, WA, China

1576

Opening Pandora’s Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Gail J. Roboz, MD¹, Nuria Mencia-Trinchant, PhD²^*, Gabriela Pereira³^*, Ellen K. Ritchie, MD⁴, Justin D. Kaner, MD⁵, Michael Samuel⁴^*, Michal Bar-Natan, MD⁴, Jonathan Canaani, MD⁶, Sharmaine Griffith-Baker⁷^*, Pinkal Desai⁸ and Monica L Guzman, PhD⁴

¹Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY
²Hematology & Medical Oncology, New York, NY
³Weill Cornell Medicine, NewYork-Presbyterian, Meyer Cancer Cente, New York
⁴Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
⁵Leukemia Program, New York-Presbyterian/Weill, Syosset, NY
⁶Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, Brooklyn, NY
⁷Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
⁸Weill Cornell Medicine New York Presbyterian Hospital, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

619.P1.28 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I